DFDA

Pembrolizumab

Treatment for Tracheal Bronchus And Lung Cancer

Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks

Effectiveness
85%
Safety Score
35%
Clinical Trials
500
Participants
50K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Time to Effect
2-4 months
Treatment Duration
Up to 2 years or until disease progression/unacceptable toxicity
Evidence Quality
HIGH
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$8,000
Side Effect Mgmt:$10,000
Total Annual:$198,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$150,000/QALY
QALYs Gained
0.46
Outcome-Based Costs
Cost per Responder
$565,714
Cost per Remission
$3,960,000
Comparison vs Platinum-based Chemotherapy
Cost Difference
+$150,000/year
More expensive
QALY Difference
+0.46 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab Outcomes

for Tracheal Bronchus And Lung Cancer

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+35%
Remission Rate
+5%
Common Side Effects
Fatigue
+40%
Nausea
+20%
Diarrhea
+20%
Pruritus
+20%
Rash
+20%
Hypothyroidism
+15%
Pneumonitis (immune-related)
+5%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov